Insider sale details
Stephen L. Sabba, a director at Ligand Pharmaceuticals INC (NASDAQ:LGND), sold 1,000 shares of the company’s common stock on March 23, 2026. The shares transacted in a sequence of trades priced between $207.850000 and $208.055000, producing an average sale price of $207.8727 and a total value of $207,872. After completing the sale, Sabba’s direct holdings in Ligand stand at 32,793 shares.
Market context
The insider sale coincides with Ligand’s stock trading at $205.74. Over the trailing 12 months the shares have delivered an 84% gain. The company’s price-to-earnings ratio is 33.6. According to InvestingPro Fair Value analysis, the stock appears overvalued. Investors interested in further valuation tools and metrics can access 11 additional ProTips and detailed financial data on InvestingPro.
Recent financial performance
Ligand reported a strong fourth quarter for 2025. The company posted adjusted earnings per share of $2.02 for the quarter, ahead of analysts' expectations of $1.49. Quarterly revenue amounted to $59.7 million, topping the consensus estimate of $55.6 million. For the full year, Ligand recorded revenue of $268 million, with core revenue reported at $240 million. Full-year adjusted EPS was $8.13.
Analyst commentary
Following the results, Oppenheimer raised its price target on Ligand to $277 while keeping an Outperform rating. Stifel reaffirmed its Buy rating and maintained a price target of $230. Both firms cited favorable views on the company’s royalty revenue prospects.
What this means
The director’s sale is a discrete transaction quantified above, and it occurred amid a broader backdrop of solid reported earnings and positive analyst notes. The company’s most recent operating metrics and the analyst price-target revisions are factual developments reported by the firm and the mentioned brokerages.
Limitations
The article reports the transaction details, the company’s recent financial results, current stock price and P/E ratio, and the InvestingPro valuation statement. It does not provide information beyond these reported items nor does it infer reasons behind the insider sale or project future stock performance.